RusfertideHepcidin mimetic
Rusfertide mimics hepcidin, the hormone that regulates iron availability. It targets erythrocytosis in polycythaemia vera, where the body produces too many red blood cells, rather than treating ordinary iron deficiency.
What is Rusfertide?
Rusfertide is a hepcidin-mimetic medicine for erythrocytosis in adults with polycythaemia vera. The FDA approved the US product Mimrylo on 28 August 2026; that statement does not establish EU or Swiss authorisation. 2 3
How it works
By mimicking hepcidin and acting on ferroportin-mediated iron availability, it restricts the iron available for red-blood-cell production. This addresses the excessive red-cell production characteristic of polycythaemia vera. 1 3
Effects studied
What does the evidence show?
Polycythaemia-vera trials and checked US approval
The problem is too many red blood cells
In polycythaemia vera, excess red blood cells can make management of haematocrit an important treatment goal. Phlebotomy removes blood to help control that measure. Rusfertide approaches the problem through iron availability, because developing red blood cells need iron to make haemoglobin.
How hepcidin signalling changes iron supply
Hepcidin acts on ferroportin, the protein that exports iron from cells into the circulation. Rusfertide mimics that signal to limit the iron available for red-cell production. This targeted restriction of iron does not amount to improving iron levels or energy in the general population.
What the treatment evidence concerns
The retained trials examined control of erythrocytosis and the need for phlebotomy. Those outcomes matter in treatment, but do not establish a cure for the blood disorder or quantify a reduction in thrombosis. Better control of haematocrit and long-term disease outcomes remain separate questions. 1
What is verified about approval
The FDA record lists Mimrylo, rusfertide, with US marketing approval dated 28 August 2026 for erythrocytosis in adults with polycythaemia vera. The checked US label confirms that indication. This is a disease-specific medicine requiring ongoing haematology care; the US decision does not establish its regulatory position elsewhere. 2 3
Safety & status
Its effect on iron regulation and red-cell production requires haematology monitoring. A treatment intended to restrict iron availability in polycythaemia vera is not a general treatment for tiredness or iron deficiency. 3
Country and product status
US FDA approval verified: Mimrylo, 28 August 2026, erythrocytosis in adults with polycythaemia vera. EU and Swiss status not verified.
Frequently asked questions
Does it cure polycythaemia vera?
The described benefit concerns controlling erythrocytosis and treatment burden, not eliminating the underlying disease. 1
Does the US approval also apply in Europe?
No. The documented FDA decision is US-specific; EU and Swiss status require their own checks. 2
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- FDA · Rusfertide approval record Primary source checked · Checked 27 October 2026: Mimrylo marketing approval 28 August 2026; erythrocytosis in adults with polycythaemia vera. US only.
- DailyMed · Mimrylo prescribing information Primary source checked · US label and indication checked 27 October 2026. Not an independent assessment of the complete trial programme.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.